Non-pegylated liposomal doxorubicin + trastuzumab + docetaxel

A combination regimen consisting of non-pegylated liposomal doxorubicin, trastuzumab, and docetaxel is used as first-line therapy in patients with metastatic breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2). Non-pegylated liposomal doxorubicin is an anthracycline antibiotic formulated in a liposome to reduce cardiotoxicity compared to conventional formulations. Trastuzumab is a monoclonal antibody targeting the HER2 receptor, inhibiting proliferation of tumor cells that overexpress this protein. Docetaxel is a taxane-class chemotherapeutic agent that promotes microtubule assembly and inhibits cell division. The combination leverages different mechanisms of action for synergistic antitumor activity while aiming to minimize overlapping toxicities, particularly cardiac toxicity associated with anthracyclines and trastuzumab. Clinical studies have shown promising response rates and manageable safety profiles for this regimen in HER2-positive metastatic breast cancer[8].

Brand names

Herceptin + Taxotere + Myocet

Other names

trastuzumab + docetaxel + liposomal doxorubicintrastuzumab/docetaxel/NPLD